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Differential Regulation of Mas-Related G Protein-Coupled Receptor X2- Mediated
Mast Cell Degranulation by Antimicrobial Host Defense Peptides and
Porphyromonas Gingivalis Lipopolysaccharide
Abstract
Porphyromonas gingivalis is a keystone pathogen that contributes to periodontal pathogenesis by
disrupting host-microbe homeostasis and promoting dysbiosis. The virulence of P. gingivalis likely
reflects an alteration in the lipid A composition of its lipopolysaccharide (LPS) from the penta-acylated
(PgLPS1690) to the tetra-acylated (PgLPS1435/1449) form. Mast cells play an important role in
periodontitis, but the mechanisms of their activation and regulation remain unknown. The expression of
epithelium- and neutrophil-derived host defense peptides (HDPs) (LL-37 and human β-defensin-3), which
activate mast cells via Mas-related G protein-coupled receptor X2 (MRGPRX2), is increased in
periodontitis. We found that MRGPRX2-expressing mast cells are present in normal gingiva and that their
numbers are elevated in patients with chronic periodontitis. Furthermore, HDPs stimulated degranulation
in a human mast cell line (LAD2) and in RBL-2H3 cells stably expressing MRGPRX2 (RBL-MRGPRX2).
PgLPS1690 caused substantial inhibition of HDP-induced mast cell degranulation, but PgLPS1435/1449 had
no effect. A fluorescently labeled HDP (FAM-LL-37) bound to RBLMRGPRX2 cells, and PgLPS1690
inhibited this binding, but PgLPS1435/1449 had no effect. These findings suggest that low-level
inflammation induced by HDP/MRGPRX2- mediated mast cell degranulation contributes to gingival
homeostasis but that sustained inflammation due to elevated levels of both HDPs and
MRGPRX2-expressing mast cells promotes periodontal disease. Furthermore, differential regulation of
HDP-induced mast cell degranulation by PgLPS1690 and PgLPS1435/1449 may contribute to the
modulation of disease progression. © 2017 American Society for Microbiology.
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Porphyromonas gingivalis is a keystone pathogen that contributes to
periodontal pathogenesis by disrupting host-microbe homeostasis and promoting
dysbiosis. The virulence of P. gingivalis likely reﬂects an alteration in the lipid A composition of its lipopolysaccharide (LPS) from the penta-acylated (PgLPS1690) to the
tetra-acylated (PgLPS1435/1449) form. Mast cells play an important role in periodontitis,
but the mechanisms of their activation and regulation remain unknown. The expression
of epithelium- and neutrophil-derived host defense peptides (HDPs) (LL-37 and human
␤-defensin-3), which activate mast cells via Mas-related G protein-coupled receptor X2
(MRGPRX2), is increased in periodontitis. We found that MRGPRX2-expressing mast cells
are present in normal gingiva and that their numbers are elevated in patients with
chronic periodontitis. Furthermore, HDPs stimulated degranulation in a human mast
cell line (LAD2) and in RBL-2H3 cells stably expressing MRGPRX2 (RBL-MRGPRX2).
PgLPS1690 caused substantial inhibition of HDP-induced mast cell degranulation, but
PgLPS1435/1449 had no effect. A ﬂuorescently labeled HDP (FAM-LL-37) bound to RBLMRGPRX2 cells, and PgLPS1690 inhibited this binding, but PgLPS1435/1449 had no effect. These ﬁndings suggest that low-level inﬂammation induced by HDP/MRGPRX2mediated mast cell degranulation contributes to gingival homeostasis but that sustained
inﬂammation due to elevated levels of both HDPs and MRGPRX2-expressing mast cells
promotes periodontal disease. Furthermore, differential regulation of HDP-induced mast
cell degranulation by PgLPS1690 and PgLPS1435/1449 may contribute to the modulation of
disease progression.
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P

eriodontitis is a bioﬁlm-induced chronic inﬂammatory disease that leads to the
destruction of the tooth-supporting structures, including alveolar bone (1). The
initial host response to bioﬁlm bacteria is a protective acute inﬂammatory response
(gingivitis) that maintains host-microbe homeostasis in the periodontium. However, the
presence of microbial factors, such as keystone pathogens (e.g., Porphyromonas gingivalis), shifts the balance toward a dysbiosis in which former commensals behave as
proinﬂammatory pathobionts (2, 3). Thus, P. gingivalis, which does not directly induce
a strong inﬂammatory response, likely contributes to pathogenesis via the subversion
or evasion of the immune system. This promotes the growth and development of a
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dysbiotic microbial community that contains a number of well-characterized Gramnegative anaerobes, such as Aggregatibacter actinomycetemcomitans, Tannerella forsythia, and Treponema denticola. Through their interactions with cells of the innate and
adaptive immune systems, these organisms contribute to the perpetuation and exacerbation of the inﬂammatory response. Ultimately, the host response elicited by the
dysbiotic microbiota induces the degradation of the soft and hard tissues characteristic
of periodontitis (2–4).
P. gingivalis has been shown to evade innate immunity via a number of mechanisms,
including inhibition of chemokine generation from epithelial cells (5) and immune
subversion via microbial exploitation of communication between the C5a receptor,
complement receptor 3 (CR3), the chemokine receptor CXCR4, and Toll-like receptor 2
(TLR2) (6, 7). It has been proposed that P. gingivalis uses these evasion maneuvers in
concert with tactics to subvert autophagy to exploit macrophages as “Trojan horses” for
subsequent infection of other cell types, and potentially for dissemination from the oral
cavity to systemic tissues (8).
P. gingivalis lipopolysaccharide (PgLPS) is one of the key virulence factors that
contribute to periodontitis (9–11). Lipid A is the most biologically active component of
LPS, and its structure differs greatly among Gram-negative bacterial species. The
canonical Escherichia coli LPS (EcLPS) possesses a hexa-acylated lipid A structure and
promotes a strong inﬂammatory response via the activation of TLR4. In contrast,
PgLPS is heterogeneous, consisting of penta-acylated (LPS1690) and tetra-acylated
(LPS1435/1449) lipid structures that generally have opposing effects on innate immune
responses, thereby playing a key role in modulating host immune-inﬂammatory reactions (10, 12, 13). It is noteworthy that P. gingivalis strains expressing penta-acylated
lipid A activate TLR4 and are more susceptible to killing by host defense peptides
(HDPs) and macrophages than strains that predominantly generate tetra-acylated lipid
A (9, 10, 14, 15). Recent studies have shown that lipid A modiﬁcations promote evasion
of the noncanonical inﬂammasome by preventing caspase-1 activation (16). Hence, the
heterogeneity of these structures is thought to play a role in oral immune homeostasis
and contributes to the microbial shift characteristic of periodontitis (2, 17, 18). Thus,
alteration of the lipid A composition of P. gingivalis may provide a strategy for it to
evade host defense mechanisms in gingival tissue, contributing to dysbiosis and
periodontal disease (9, 10).
Mast cells are multifunctional immune cells that are found in all vascularized tissues
throughout the body, including the gingiva, and they play a critical role in host defense
(19–21). This function of mast cells is mediated via the release of proteases, which
degrade ﬁbrinogen and disrupt tight junctions, leading to the transmigration of
neutrophils across the vascular endothelium (22). It has been proposed that mast cells
contribute to both gingival homeostasis and periodontitis (23–28). Not surprisingly,
mast cells are found in healthy gingiva and in gingivitis lesions. Their numbers are
increased in chronic periodontitis (CP), and the degree of their degranulation correlates
well with disease severity (23, 25–27, 29, 30). Malcolm et al. (31) recently showed that
mast-deﬁcient (Wsh/Wsh) mice are protected from P. gingivalis-induced periodontal
bone loss. Furthermore, restoration of mast cells in Wsh/Wsh mice resulted in P. gingivalisinduced bone loss that was associated with increased mast cell degranulation. Based on
these ﬁndings, it has been proposed that mast cell degranulation plays an important role
in periodontal bone loss. However, the mechanisms of mast cell activation and regulation
in periodontitis remain unknown.
Mas-related G protein-coupled receptor X2 (MRGPRX2; previously named MrgX2) is
expressed on human mast cells and contributes to host defense, pseudoallergic drug
reactions, and chronic inﬂammatory diseases, such as chronic urticaria (32–36). Given
that mast cells are tissue-resident cells and are found close to the blood vessels, it is
likely that they are activated by mediators derived from the epithelium and from
invading neutrophils. Indeed, antimicrobial HDPs released from the epithelium (human
␤-defensins [hBDs]) and from neutrophils (the cathelicidin LL-37) cause both mast cell
chemotaxis and degranulation via the activation of MRGPRX2 (37–42). It is noteworthy
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that expression of HDPs is upregulated in the gingiva and saliva of patients with
periodontitis compared to that in the gingiva and saliva of healthy subjects (43–48).
These ﬁndings suggest that MRGPRX2-mediated activation of mast cells by HDPs
contributes to host defense. It is also plausible that the recruitment and activation
of mast cells via MRGPRX2 in response to elevated levels of HDPs found in patients
with periodontitis are involved in the cascade of events leading to alveolar bone
loss. However, the possibility that mast cells residing within periodontal tissues
express MRGPRX2 has not previously been determined.
The purpose of this study was 2-fold: (i) to determine if MRGPRX2 is expressed in
gingival tissues obtained from healthy subjects as well as from patients with CP and (ii)
to characterize the effects of PgLPS1690 and PgLPS1435/1449 on HDP-induced mast cell
signaling and degranulation. The data presented herein demonstrate increased levels
of MRGPRX2-expressing mast cells in CP patients compared to those in healthy subjects
and suggest a previously unrecognized cross talk between HDPs and PgLPS, which may
be relevant to gingival homeostasis and periodontal disease.
RESULTS
MRGPRX2-tryptase double-positive mast cells are present in healthy gingiva,
and their numbers are increased in CP gingiva. Recent studies demonstrated that
mast cell numbers are increased in CP gingiva compared to those in healthy gingiva
or gingivitis lesions (23, 25–27, 29, 30), with the degree of mast cell degranulation
correlating well with disease severity (25). In contrast, an earlier study showed a
decrease in mast cells in CP gingiva compared to the level in normal gingiva (49).
Therefore, our ﬁrst goal was to determine the status of mast cells in normal and CP
gingival samples. Immunohistochemical (IHC) analysis with anti-tryptase antibody revealed that mast cells were present in gingival tissues from both healthy subjects and
patients with CP (Fig. 1A and B). Quantitative analysis demonstrated a signiﬁcant
increase in mast cell numbers in CP patients compared to the numbers in healthy
subjects (Fig. 1C).
MRGPRX2 is expressed on human skin mast cells and dorsal ganglia but not in other
immune or structural cells (36, 50, 51). To determine if MRGPRX2 is expressed in human
gingival mast cells, we performed immunoﬂuorescence (IF) staining with anti-tryptase
and anti-MRGPRX2 antibodies. Consistent with the immunohistochemistry data (Fig. 1),
mast cells were detected in normal gingiva, and their numbers were increased in CP
gingiva (Fig. 2B and C, green cells). MRGPRX2 was also expressed in normal gingival
October 2017 Volume 85 Issue 10 e00246-17
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FIG 1 IHC analysis of mast cells in periodontal tissues from healthy subjects and patients with CP. Healthy gingivae (A) and
gingivae from patients diagnosed with CP (B) were stained with anti-human mast cell tryptase antibody. Representative
photomicrographs are shown. Bars ⫽ 2 mm (left) and 200 m (right). (C) Quantitative analysis of mast cells was done by
counting mast cells in a total of 75 high-power ﬁelds (HPF) from 5 different tissue sections of both healthy and CP gingivae.
Data presented are means and SEM for mast cell counts for 5 donors. Statistical signiﬁcance was determined by two-way
ANOVA with Bonferroni’s posttest (*, P ⬍ 0.01).
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tissue, and the number of cells expressing this receptor was increased in CP tissue (Fig.
2B and C, red cells). The overlay images in Fig. 2B and C show that mast cells in both
normal and CP samples expressed MRGPRX2 (yellow cells). These ﬁndings demonstrate
that MRGPRX2-expressing mast cells are present in normal periodontal tissue and that
their numbers are increased in CP tissues. We found that several MRGPRX2-expressing
cells were not stained by use of anti-tryptase antibody (Fig. 2, overlay images). Fujisawa
et al. (50) recently showed that in the skin of patients with chronic urticaria, most
MRGPRX2⫹ cells are mast cells, with nerve cells accounting for ⬃10% of MRGPRX2expressing cells. Similarly, the MRGPRX2⫹ tryptase⫺ cells in the gingiva are likely to be
nerve cells.
PgLPS1690 inhibits HDP-induced Ca2ⴙ mobilization and degranulation in human LAD2 mast cells, but PgLPS1435/1449 does not. MRGPRX2 expressed on human
mast cells is activated by epithelium- and neutrophil-derived HDPs, i.e., hBD3 and LL-37
(37, 38). Mast cells are activated via two major pathways: high-afﬁnity IgE receptors
(FcRI) and G protein-coupled receptors (GPCRs), such as MRGPRX2 (52). While mast cell
activation via both pathways results in intracellular Ca2⫹ mobilization, signaling via
FcRI leads to degranulation and cytokine generation, but MRGPRX2 activation causes
strong degranulation and little to no cytokine generation (52). We therefore wanted to
determine if PgLPS1690 and PgLPS1435/1449 modulate HDP-induced degranulation in
human mast cells. Because of the difﬁculty in obtaining sufﬁcient numbers of human
tissue mast cells, a number of laboratories, including our own, have utilized a human
mast cell line, LAD2, for functional studies (32, 38, 50). Although there are limitations
associated with the use of cell lines, LAD2 cells are well characterized and express
functional MRGPRX2 (33, 34, 37, 38). hBD3 (100 nM) and LL-37 (1 M) caused intracellular Ca2⫹ mobilization (Fig. 3A and D). Preincubation of cells with PgLPS1690 did not
induce Ca2⫹ mobilization but resulted in substantial inhibition of the responses to both
hBD3 and LL-37 (Fig. 3, panel A versus panel B and panel D versus panel E). The
complement component C3a activates human mast cells via a GPCR, the C3a receptor
(53, 54). To determine the speciﬁcity of PgLPS1690 for HDPs, we tested its effect on Ca2⫹
mobilization induced by C3a. While PgLPS1690 inhibited Ca2⫹ responses to HDPs, it had
no effect on the response to C3a (Fig. 3, panel A versus panel B and panel D versus
panel E). Unlike PgLPS1690, PgLPS1435/1449 did not inhibit the hBD3- or LL-37-induced
Ca2⫹ responses (Fig. 3, panel A versus panel C and panel D versus panel F).
Mast cells express TLR2 and TLR4, key receptors for LPS recognition, yet previous
studies have shown that PgLPS does not induce degranulation in rat peritoneal mast
October 2017 Volume 85 Issue 10 e00246-17
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FIG 2 Analysis of tryptase- and MRGPRX2-positive mast cells in periodontal tissue. Representative photomicrographs (n ⫽ 5 donors) of double immunoﬂuorescence staining of gingival tissue are shown. Original
magniﬁcation, ⫻60. (A) Control. (B and C) A healthy gingiva (B) and the gingiva of a patient with CP (C) were
stained with anti-tryptase (green) and anti-MRGPRX2 (red) antibodies. Overlays of double-staining samples
are shown. Bars ⫽ 50 m.
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cells (55). Similarly, we found that PgLPS1690 and PgLPS1435/1449 did not cause degranulation in human LAD2 cells (Fig. 4A and B). However, preincubation of LAD2 cells with
PgLPS1690 resulted in substantial inhibition of degranulation in response to both hBD3
and LL-37 (Fig. 4A and B) but had no effect on the response to C3a (Fig. 4E). In contrast,
PgLPS1435/1449 had no effect on degranulation in response to hBD3, LL-37, or C3a (Fig.
4C to E).
PgLPS1690 has no effect on cell surface MRGPRX2 expression but inhibits
degranulation through its association with LL-37. LPS treatment has been shown to
alter the phenotype and function of mast cells (56). It is therefore possible that
PgLPS1690 can inhibit HDP-induced mast cell degranulation via downregulation of
MRGPRX2. To test this possibility, we ﬁrst determined the effects of PgLPS1690 and
PgLPS1435/1449 on cell surface expression of MRGPRX2 on transfected RBL-2H3 (RBLMRGPRX2) cells by ﬂow cytometry. In untransfected RBL-2H3 cells, there was minimal
binding of anti-MRGPRX2 antibody, which was increased ⬃20-fold in RBL-MRGPRX2
cells. There was no signiﬁcant change in MRGPRX2 expression upon incubation of cells
with either PgLPS1690 or PgLPS1435/1449 (Fig. 5A, left panel). Similarly, PgLPS1690 or
PgLPS1435/1449 pretreatment had no effect on cell surface MRGPRX2 on LAD2 cells,
which natively express the receptor (Fig. 5A, right panel). These ﬁndings suggest that
the inhibitory effect of PgLPS1690 on HDP-induced mast cell degranulation is not
mediated via the downregulation of cell surface MRGPRX2.
Similar to that in human LAD2 cells (Fig. 4), hBD3- and LL-37-induced degranulation
in RBL-MRGPRX2 cells was inhibited by PgLPS1690 but not by PgLPS1435/1449 (Fig. 5B and
C). Because PgLPS1690 did not modulate cell surface MRGPRX2 expression (Fig. 5A), we
sought to determine if it inhibits the binding of ligand to the receptor. To test this
possibility, we utilized ﬂuorescence-labeled LL-37 (FAM-LL-37) and RBL-MRGPRX2 cells.
We found that FAM-LL-37 bound to RBL-MRGPRX2 cells but not to untransfected cells
(Fig. 5D). Furthermore, preincubation with PgLPS1690 prevented the binding of FAMOctober 2017 Volume 85 Issue 10 e00246-17
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FIG 3 PgLPS1690 inhibits hBD3- and LL-37-induced Ca2⫹ mobilization in LAD2 cells, but PgLPS1435/1449 does not. (A and D) Indo-1-loaded cells were sequentially
exposed to hBD3 (100 nM) or LL-37 (1 M) and C3a (10 nM), and intracellular Ca2⫹ mobilization was determined. (B and E) Cells were pretreated with PgLPS1690
(10 g/ml) before exposure to hBD3 (100 nM) or LL-37 (1 M) and C3a (10 nM), and intracellular Ca2⫹ mobilization was determined. (C and F) Cells were
pretreated with PgLPS1435/1449 (10 g/ml) before exposure to hBD3 (100 nM) or LL-37 (1 M) and C3a (10 nM), and intracellular Ca2⫹ mobilization was
determined. Traces are representative of three independent experiments.
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LL-37 to RBL-MRGPRX2 cells, which was associated with inhibition of FAM-LL-37induced degranulation (Fig. 5B). Conversely, PgLPS1435/1449, which did not block LL37-induced mast cell degranulation (Fig. 5B), had no inhibitory effect on FAM-LL-37
binding to RBL-MRGPRX2 cells (Fig. 5D).
There are two possible mechanisms by which PgLPS1690 inhibits LL-37/MRGPRX2mediated mast cell degranulation. One involves a direct interaction of anionic PgLPS1690
with the cationic LL-37 molecule, and the other occurs via binding of LPS to MRGPRX2
on mast cells, where it may function as a receptor antagonist. To distinguish
between these possibilities, we premixed PgLPS1690 and FAM-LL-37 and tested the
ability of LPS to modulate MRGPRX2-mediated degranulation. We found that
PgLPS1690 inhibited FAM-LL-37-induced degranulation without requiring preincubation (Fig. 6A). Furthermore, when cells were washed to remove the mixture and
restimulated with FAM-LL-37, there was restoration of degranulation. Premixing of
FAM-LL-37 with PgLPS1690 prevented the ability of the ligand to bind to MRGPRX2
(Fig. 6B). Furthermore, when the cells were washed to remove the PgLPS1690/FAMLL-37 and then restimulated with FAM-LL-37, there was restoration of ligand binding to
the receptor (Fig. 6B). These ﬁndings suggest that PgLPS1690 inhibits LL-37-induced
mast cell degranulation via its interaction with ligand rather than by acting as an
MRGPRX2 antagonist.
DISCUSSION
This study provides the ﬁrst demonstration that MRGPRX2-expressing mast cells are
present in normal gingival tissue and that their numbers are increased in patients with
CP. The unique features of MRGPRX2 are that it is selectively expressed in mast cells and
no other immune cells and that it is activated by multiple cationic ligands, such as HDPs
(hBDs, the cathelicidin LL-37, retrocyclin, and protegrin), neuropeptides (substance P
and cortistatin), and eosinophil granule proteins (major basic protein [MBP] and
eosinophil peroxidase), as well as by a number of FDA-approved cationic drugs (32,
October 2017 Volume 85 Issue 10 e00246-17
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FIG 4 PgLPS1690 inhibits hBD3- and LL-37-induced degranulation in LAD2 cells, but PgLPS1435/1449 does not. (A to D) Cells were pretreated with buffer (control),
PgLPS1690 (1 or 10 g/ml, 5 min) (A and B), or PgLPS1435/1449 (1 or 10 g/ml, 5 min) (C and D) and then exposed to hBD3 (100 nM, 30 min) or LL-37 (1 M, 30
min), and degranulation (␤-hexosaminidase release) was determined. (E) Cells were pretreated with PgLPS1690 (10 g/ml, 5 min) or PgLPS1435/1449 (10 g/ml,
5 min) and then exposed to C3a (10 nM, 30 min), and degranulation (␤-hexosaminidase release) was determined. Data are means and SEM for three
independent experiments. Statistical signiﬁcance was determined by two-way ANOVA with Bonferroni’s posttest (*, P ⬍ 0.01; **, P ⬍ 0.001).
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FIG 5 PgLPS1690 has no effect on MRGPRX2 expression but inhibits degranulation through its association with LL-37. (A) RBL-MRGPRX2 (left) or LAD2 (right) cells
were incubated at 37°C for 5 min with buffer (control), PgLPS1690 (50 g/ml), or PgLPS1435/1449 (50 g/ml). The reaction was stopped, and the cell surface
MRGPRX2 level was determined by ﬂow cytometry as described in Materials and Methods. MFI, mean ﬂuorescence intensity. Untransfected RBL cells and LAD2
cells incubated with an isotype-matched antibody were used as controls. ns, not signiﬁcant. (B and C) RBL-MRGPRX2 cells were preincubated with buffer,
PgLPS1690, or PgLPS1435/1449 at 37°C for 5 min and then exposed to LL-37 (3 M, 30 min) (B) or hBD3 (300 nM, 30 min) (C), and degranulation (␤-hexosaminidase
release) was determined. Results are the means and SEM for three independent experiments. Statistical signiﬁcance was determined by two-way ANOVA with
Bonferroni’s posttest (**, P ⬍ 0.001). (D) Untransfected RBL cells (ﬁrst panel) and RBL-MRGPRX2 cells (second panel) were exposed to FAM-LL-37 (1 M) and
analyzed by confocal microscopy. RBL-MRGPRX2 cells were preincubated with PgLPS1690 (50 g/ml) (third panel) or PgLPS1435/1449 (50 g/ml) (last panel),
exposed to FAM-LL-37 (1 M, 30 min), and analyzed by confocal microscopy. Bars ⫽ 20 m.

36–38, 50, 57). Activation of MRGPRX2 contributes to host defense, pseudoallergic
drug reactions, and chronic inﬂammatory diseases, such as chronic urticaria (32, 33,
35). The data presented herein suggest that MRGPRX2 contributes to both gingival
homeostasis and CP and that differential regulation of HDP-induced mast cell
October 2017 Volume 85 Issue 10 e00246-17
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degranulation by PgLPS1690 and PgLPS1435/1449 has a role in the modulation of
disease progression.
The epithelium and inﬁltrating neutrophils play an important role in gingival
homeostasis, in part via the secretion of HDPs, such as defensins and the cathelicidin
LL-37 (58). These cationic HDPs have direct antimicrobial activities due to their ability
to bind to negatively charged residues on microbial membranes, thereby forming pores
(59, 60). In addition, HDPs modulate the host response and wound healing via the
recruitment and activation of mast cells, monocytes, and T cells (58, 61–64). It now
appears that these properties play a greater role in host defense against microbial
infection than their direct antimicrobial activity (65, 66). We recently showed that HDPs
induce mast cell degranulation via MRGPRX2 (33, 34, 37, 38). Based on these ﬁndings,
we proposed that MRGPRX2 contributes to the host defense following microbial
infection. It is noteworthy that two types of human mast cells have been identiﬁed
based on the protease content of their secretory granules. Mast cells that are found in
the connective tissue of skin contain both tryptase and chymase and are known as
MCTC (67, 68). In contrast, the majority of mast cells that are found in the lungs and gut
express only tryptase and are known as MCT. Recent studies demonstrated that while
skin MCTC express MRGPRX2 at high levels, lung mast cells do not (50). Taken together,
these ﬁndings imply that the ability of LL-37 and hBDs to modulate host defense
and wound healing is restricted to tissues that contain MRGPRX2-expressing MCTC.
In the present study, we have shown that mast cells in healthy gingival tissue
express MRGPRX2. This suggests that HDPs derived from oral epithelial cells and
inﬁltrating neutrophils found in normal tissue (69) contribute to gingival homeostasis by inducing mast cell degranulation via MRGPRX2. This effect is likely mediated
via the action of mast cell-derived proteases that cause increased vascular permeability
and disrupt tight junctions, leading to the transmigration of neutrophils across the
vascular endothelium (22).
Studies with human subjects and a mouse model of periodontitis suggested that
mast cell degranulation contributes to periodontal bone loss (25–27, 29, 31). However,
the mechanisms of mast cell activation and regulation in periodontitis have not been
determined. The ﬁndings of the current study provide the ﬁrst demonstration that a
signiﬁcant increase in MRGPRX2-expressing mast cells is present in CP patients compared to the level in gingival tissue of healthy subjects. Considered in the context of
studies reporting enhanced expression of hBDs and LL-37 in inﬂamed periodontal
tissue relative to that in healthy tissue (43–48), it is feasible that HDP-induced gingival
mast cell degranulation via MRGPRX2 contributes to periodontal disease progression. In total, these ﬁndings imply that while low-level inﬂammation induced by
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FIG 6 PgLPS1690 inhibits FAM-LL-37-induced mast cell degranulation through association with LL-37, not MRGPRX2. (A) RBL-MRGPRX2 cells were
exposed to FAM-LL-37 (3 M) or premixed PgLPS1690 (50 g/ml) and FAM-LL-37 (3 M) for 30 min, and degranulation was determined. In addition,
the PgLPS1690/FAM-LL-37 mixture was removed by washing, the cells were reexposed to FAM-LL-37 for 30 min, and degranulation was
determined. Data are means and SEM for three independent experiments. Statistical signiﬁcance was determined by two-way ANOVA with
Bonferroni’s posttest (**, P ⬍ 0.001). (B) Samples from each of the three experimental conditions described for panel A were used for confocal
microscopy analyses, and representative photomicrographs are shown. Bars ⫽ 10 m.

Infection and Immunity

HDP/MRGPRX2-mediated mast cell degranulation contributes to gingival homeostasis,
sustained inﬂammation, associated with elevated levels of both HDPs and MRGPRX2expressing mast cells, promotes periodontal disease.
The observation that PgLPS1690 inhibits HDP-induced degranulation of human mast
cells via MRGPRX2 is intriguing, and its signiﬁcance is currently unknown. It is plausible
that during gingival homeostasis PgLPS1690 inhibits HDP-induced mast cell degranulation, thus compromising host defense. However, due to the relative absence of
pathogens associated with homeostasis, there might be an insufﬁcient amount of
PgLPS1690 to inhibit mast cell degranulation induced by HDPs released from resident
epithelial cells and recruited neutrophils. Furthermore, it is conceivable that the virulence of P. gingivalis reﬂects an alteration in the lipid A composition of its LPS from
PgLPS1690 to PgLPS1435/1449, implying that PgLPS1690 contributes to gingival homeostasis. Thus, the possibility that PgLPS1690 disrupts gingival homeostasis by inhibiting
the HDP/MRGPRX2-mediated host defense function of mast cells is unlikely.
In periodontal disease, both HDP levels (43–48) and the number of MRGPRX2expressing mast cells are elevated (Fig. 2). Thus, PgLPS1690 may serve to control disease
progression by blocking MRGPRX2-expressing mast cell-mediated inﬂammation, thereby
providing a novel mechanism for obstructing the growth of proinﬂammatory pathobionts. It has been shown that hemin, a component of gingival crevicular ﬂuid, has an
impact on the generation of different types of PgLPS (9). Thus, low concentrations of
hemin lead to the generation of mostly penta-acylated lipid A structures, but at high
concentrations mostly tetra-acylated lipid A structures are found (9). Consequently, it is
likely that alteration of the lipid A composition from the penta- to the tetra-acylated
form in the presence of a high hemin concentration removes PgLPS1690’s inhibitory
signal for blocking mast cell degranulation. Under the inﬂuence of high levels of hemin,
preferential synthesis of PgLPS1435/1449, which does not inhibit HDP-induced mast cell
degranulation, may represent a previously unrecognized strategy for P. gingivalis to
evade host defense mechanisms in gingival tissue, thereby contributing to dysbiosis
and the pathogenesis of periodontal disease.
In addition to chronic inﬂammation at the initial site of infection, P. gingivalis also
contributes to systemic inﬂammation, such as atherosclerosis, which is dependent
on the presence of mast cells (70–73). The differential effects of PgLPS1690 and
PgLPS1435/1449 on HDP/MRGPRX2-mediated mast cell degranulation may therefore
modulate chronic inﬂammatory reactions at distal sites. In this context, P. gingivalis
mutants with differences in the lipid A composition of LPS were recently shown to vary
in the ability to modulate systemic chronic inﬂammation (15). Thus, similar P. gingivalis
mutants may be required for future studies to delineate the roles of PgLPS, HDP, and
MRGPRX2 in mast cell-mediated local periodontal pathogenesis and distal chronic
inﬂammatory diseases, such as atherosclerosis.
The mechanism by which PgLPS1690 modulates HDP-induced signaling and mast cell
degranulation has not been determined. PgLPS1690 stimulates autophagy in Saos-2
osteosarcoma cells, and this effect is reversed by PgLPS1435/1449 (74). Furthermore,
autophagy is critical for IgE-dependent mast cell degranulation (75). The ﬁnding in the
present study that PgLPS1690 inhibits MRGPRX2-mediated mast cell degranulation
suggests that autophagy is unlikely to be involved. One possibility is that PgLPS1690
binds to MRGPRX2 and acts as a receptor antagonist to inhibit HDP-induced mast cell
responses. This is unlikely for several reasons. We found that although preincubation of
cells with PgLPS1690 both prevented binding of FAM-LL-37 to MRGPRX2 and blocked
degranulation, similar results were obtained when cells were exposed to premixed
PgLPS1690 and FAM-LL-37. Furthermore, when cells were washed to remove the
PgLPS1690 and FAM-LL-37 mixture and restimulated with FAM-LL-37, there was
restoration of degranulation, and this was associated with binding of FAM-LL-37 to
MRGPRX2. These ﬁndings suggest that the mechanism via which PgLPS1690 inhibits
LL-37-induced mast cell degranulation does not involve a direct antagonist effect on
MRGPRX2 but may be mediated via its interaction with ligand. We recently showed that
E. coli LPS also inhibits hBD3- and LL-37-induced degranulation in mast cells (34).
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Thus, it is likely that electrostatic interactions between negatively charged E. coli
LPS or PgLPS1690 and cationic HDPs provide similar mechanisms for the modulation
of MRGPRX2-mediated degranulation in human mast cells.
In summary, the data presented herein suggest that mast cells play important roles
in both gingival homeostasis and periodontal disease by orchestrating an interaction
between gingival epithelial cells and neutrophils via MRGPRX2-mediated degranulation. In vivo studies with wild-type and mast cell-deﬁcient mice have demonstrated an
important role for mast cells in P. gingivalis-induced periodontal inﬂammation and
bone loss (31). A mouse ortholog (MrgprB2) of human MRGPRX2 was recently identiﬁed, and similar to the situation in humans, this receptor appears to be expressed only
in mast cells (32). Thus, future in vivo studies with MrgprB2 knockout mice should
provide new information on the role of this receptor in periodontal health and disease.

Materials. All cell culture reagents were purchased from Invitrogen (Gaithersburg, MD). Native
complement C3a was obtained from Complement Technology (Tyler, TX). hBD3, LL-37, and FAM-LL-37
were purchased from Anaspec (Freemont, CA). PgLPS1690 and PgLPS1435/1449 were obtained from Astarte
Biologics (Redmond, WA). Anti-human tryptase antibody was purchased from Santa Cruz (Dallas, TX), and
anti-human MRGPRX2 antibody was obtained from Novus Biologicals (Littleton, CO). 4=,6-Diamidino-2phenylindole (DAPI), ProLong Gold antifade reagent, Alexa Fluor 488-conjugated donkey anti-mouse IgG,
and Alexa Fluor 594-conjugated donkey anti-rabbit IgG were purchased from Molecular Probes Inc.
(Eugene, OR). Vectastain ABC kits and NovaRED peroxide substrate were obtained from Vector Laboratories, Inc. (Burlingame, CA). Phycoerythrin (PE)-conjugated anti-human MRGPRX2 antibody was obtained from BioLegend (San Diego, CA).
Human gingival tissue. Human gingival tissue samples were obtained during routine periodontal
surgery performed at the University of Pennsylvania, School of Dental Medicine. In all cases, the donated
tissue represented secondary gingival ﬂaps that were typically discarded upon removal from the
patient’s mouth. Healthy tissue came from individuals free of periodontal disease presenting for clinical
crown-lengthening surgery. Diseased tissue was procured from individuals diagnosed with CP who
presented for pocket reduction surgery. Upon removal, tissue was immediately placed in cold F-12
medium supplemented with 1% antibiotic-antimycotic solution and transported to the laboratory on ice
for further processing. The protocol for tissue procurement was approved by the University of Pennsylvania Institutional Review Board, and all donors provided informed consent.
IHC. Immunohistochemical (IHC) staining was performed on 5-m-thick, parafﬁn-embedded healthy
and CP gingiva sections by using a mouse anti-human MC tryptase monoclonal antibody as described
previously (25), with some modiﬁcations. Brieﬂy, deparafﬁnized, hydrated, and antigen-retrieved sections
were incubated with anti-human tryptase (1:500 dilution) at 4°C overnight. An isotype control antibody
or incubations without primary antibody served as experimental controls. Sections were washed three
times with phosphate-buffered saline containing 0.1% Tween 20 (PBST) and then incubated with
biotinylated horse anti-mouse IgG for 30 min. Detection was done using a Vectastain ABC kit. NovaRED
peroxidase substrate solution was employed as the chromogen. The sections were then counterstained
with Mayer’s hematoxylin and mounted using Permount medium. Images were captured using a Nikon
E600 microscope with a digital camera attached.
IF assay of human gingival tissue. Immunoﬂuorescence (IF) staining was performed on 5-m-thick,
parafﬁn-embedded sections prepared from healthy and CP gingiva. Brieﬂy, deparafﬁnized, hydrated, and
antigen-retrieved sections were incubated with anti-human tryptase (1:750 dilution) overnight at 4°C. An
isotype control antibody or incubations without primary antibody served as experimental controls.
Sections were then washed thrice with PBST and incubated with secondary antibody, i.e., Alexa Fluor
488-conjugated donkey anti-mouse (1:400 dilution), in conjunction with DAPI (1:4,000) for 1 h at room
temperature in the dark. Subsequently, sections were washed three times with PBST and incubated
overnight at 4°C with anti-human MRGPRX2 (1:500). The following day, sections were washed and
incubated with Alexa Fluor 594-conjugated donkey anti-rabbit IgG (1:400 dilution) at room temperature
in the dark for 1 h. The tissue sections were then washed and mounted with ProLong Gold antifade
reagent. Images were captured using a Nikon A1R laser scanning confocal microscope with a 60⫻ water
objective (numerical aperture [NA] ⫽ 1.2) and analyzed using Nikon Elements and Adobe Photoshop
software.
Human mast cell culture. The human mast cell line LAD2 was maintained in complete StemPro-34
medium supplemented with L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin (100 g/ml), and
recombinant human stem cell factor (rhSCF) (100 ng/ml). Hemidepletions were performed weekly with
medium containing rhSCF (100 ng/ml) (76).
Transfection of RBL-2H3 cells. Cells were transfected with plasmids encoding hemagglutinin
(HA)-tagged MRGPRX2 by use of an Amaxa Nucleofector device and an Amaxa kit V according to the
manufacturer’s protocol. Following transfection, cells were cultured in the presence of G418 (1 mg/ml),
and cells expressing equivalent levels of the receptor were sorted using an anti-HA speciﬁc antibody and
ﬂuorescein isothiocyanate (FITC)-conjugated anti-mouse IgG (35, 37, 77).
The LAD2 and RBL-2H3 cells used in this study were authenticated by determining the expression of
FcRI and c-Kit by ﬂow cytometry.
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Calcium mobilization. Ca2⫹ mobilization was determined as described previously (37). Brieﬂy, LAD2
mast cells (0.2 ⫻ 106) were loaded with 1 M indo-1 AM for 30 min at room temperature. Cells were
washed and resuspended in 1.5 ml of HEPES-buffered saline. Ca2⫹ mobilization was measured using a
Hitachi F-2500 spectrophotometer, with an excitation wavelength of 355 nm and an emission wavelength of 410 nm.
Degranulation. LAD2 (5 ⫻ 103) and RBL-MRGPRX2 (5 ⫻ 104) cells were seeded into 96-well plates
in a total well volume of 50 l HEPES buffer containing 0.1% bovine serum albumin (BSA) and pretreated
with PgLPS1690 or PgLPS1435/1449 for 5 min before stimulation with the indicated peptides for 30 min. Cells
without LPS treatment were designated controls. For total ␤-hexosaminidase release, unstimulated cells
were lysed in 50 l of 0.1% Triton X-100. Aliquots (20 l) of supernatants or cell lysates were incubated
with 20 l of 1 mM p-nitrophenyl-N-acetyl-␤-D-glucosamine for 1.5 h at 37°C. The reaction was stopped
by adding 250 l of a 0.1 M Na2CO3/0.1 M NaHCO3 buffer, and absorbance was measured at 405 nm (37).
Flow cytometry. Untransfected RBL-2H3 or RBL-MRGPRX2 cells and LAD2 cells (0.5 ⫻ 105/50 l) were
preincubated with either PgLPS1690 or PgLPS1435/1449 (50 g/ml) for 5 min at 37°C. Cells were incubated
with PE-conjugated anti-human MRGPRX2 antibody (0.2 g) for 30 min on ice. Cells were washed in
ﬂuorescence-activated cell sorter (FACS) buffer (PBS containing 2% fetal calf serum [FCS] and 0.02%
sodium azide) and ﬁxed in 300 l 1.5% paraformaldehyde. Cells were acquired using a BD LSR II ﬂow
cytometer (San Jose, CA), and the resulting data were analyzed using WinList software, version 8.
Confocal microscopy. Untransfected RBL-2H3 or RBL-MRGPRX2 cells (1 ⫻ 105) were stimulated with
FAM-LL-37 at 37°C for 30 min in the presence or absence of PgLPS1690 or PgLPS1435/1449. Cells were then
washed and stimulated with FAM-LL-37 at 37°C for 30 min. After washing three times with PBS, samples
were ﬁxed with 1.5% formaldehyde and cytospun onto glass slides. Images were captured using a Nikon
A1R laser scanning confocal microscope with a 60⫻ water objective (NA ⫽ 1.2) and analyzed using Nikon
NIS Elements software.
Statistical analysis. Data were expressed as means ⫾ standard errors of the means (SEM) for 3 to
5 independent experiments, and statistical signiﬁcance was determined by two-way analysis of variance
(ANOVA) with Bonferroni’s posttest. The signiﬁcance of differences is indicated in the ﬁgures and was
analyzed by use of GraphPad Prism, version 5.01.
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